Project Danube: Multi-Cancer and Comorbidity Blood Sample Collection for Cross-Reactivity Analysis for a Multiomics CRC Screening Test
The purpose of this study is to determine the efficacy of Freenome's blood test for Colorectal Carcinoma (CRC) and advanced adenoma (polyp or small cluster of cells) among various non-CRC cancer types and non-cancerous gastrointestinal diseases.
Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, Breast Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Stomach Cancer, Genitourinary Cancer, Gynecological Cancer, Upper Gastrointestinal Cancer, Hematologic Malignancies.
1. 45-85 years of age within 30 days of enrollment.
2. Negative for CRC and adenomas (polyp or small cluster of cells) screening results in the number of years prior to enrollment through chart review or self-reporting: colonoscopy 9 years, sigmoidoscopy or CT colonography 4 years, or stool DNA test 2 years.
3. Should meet one of the following conditions at the time of enrollment:
a) Clinical diagnosis with histopathlological confirmation (including staging) of single primary cancer of the breast, prostate, lung, liver, pancreas, stomach, genitourinary, gynecological, upper gastrointestinal, and hematologic malignancies must be present.
b) Clinical diagnosis of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis (UC) or Crohn's Disease (CD) must be present.
c) No history of Cancer.
4. Able and willing to provide blood samples per protocol prior to any types of treatments (systemic and/or non-systemic treatments, such as surgery, radiation or chemotherapy).
5. Able to comprehend and willing to sign and date the informed consent document(s).
45 - 85
Healthy Volunteers Needed
Duration of Participation
The study will consist of 1 visit. Study duration for each participant will be approximately 30 minutes to go over eligibility, medical history, and blood sample collection. Participants in the Control Cohort may also be contacted by site personnel once a year for up to 3 years following the completion of the study to gather additional information (e.g., any new cancer diagnosis).
$100 reimbursement for travel and parking expenses.